Switch View
© PR Newswire
07.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of the securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NUTX
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex " or "the Company") (NASDAQ: NUTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities a...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
07.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
07.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: CA00830Q3061
Affinor Growers Inc.
AFI
LISTED
CSE
Canadian Investment Regulatory Organization Trading Halt - AFI
News Preview
VANCOUVER, BC, Oct. 7, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Affinor Growers Inc.
CSE Symbol: AFI
All Issues: Yes
Reason: Cease Trade Order
Halt Time (ET): 7:32 AM
CIRO can make a decision to impose a tempo...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulg...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exc...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US04280A1007
Arrowhead Pharmaceuticals Inc
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyper...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US74340E1038
Progyny Inc
PGNY
LISTED
NASDAQ
Progyny CEO Named World Economic Forum Champion for Women’s Health
News Preview
Progyny joins global leaders to accelerate advancement in research, innovation, and resilience in women’s health Progyny joins global leaders to accelerate advancement in research, innovation, and resilience in women’s health...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SMLR
News Preview
LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler " or "the Company") (NASDAQ: SMLR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securi...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
07.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LFMD
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD " or "the Company") (NASDAQ: LFMD ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and E...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pr...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US64049M2098
Neogenomics Inc
NEO
LISTED
NASDAQ
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
News Preview
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbi...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US8106481059
scPharmaceuticals, Inc.
SCPH
LISTED
NASDAQ
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
News Preview
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc....
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
News Preview
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investor...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US45168D1046
IDEXX Laboratories, Inc.
IDXX
LISTED
NASDAQ
IDEXX Laboratories Elects Karen Peacock to Board of Directors
News Preview
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025.
"We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it’s oral, once-daily L-protein inhibitor, both in development for t...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company’s recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US74587B1017
Pulse Biosciences Inc
PLSE
LISTED
NASDAQ
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the upcoming presentation of early clinical data on the treatment of atrial fibrillation (AF) using the nPulse™ Cardiac Surgical System at the 39th Euro...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US56400P2011
MannKind Corporation
MNKD
LISTED
NASDAQ
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
News Preview
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US74276R1023
Privia Health Group Inc
PRVA
LISTED
NASDAQ
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6
News Preview
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US6700021040
Novavax Inc
NVAX
LISTED
NASDAQ
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
News Preview
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi to take full responsibility for commercial and regulatory activities in the EU. The tran...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies” in the Journal of the National Cancer Institute.1 The modeling study found that Cologuard Plus™, a triennial next-ge...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase 1 study evaluating ADI-001 as a potential treatment for...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Completes Acquisition of Verona Pharma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Mark...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
News Preview
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission
At four years, nearly all patients who achieved clinical remission at one y...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group Signs Real Estate for Corporate Combo Store of iQ Food Co. and Heal Wellness in Toronto, Ontario
News Preview
Toronto, Ontario--(Newsfile Corp. - October 7, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce the securing of a new prime real estate location in Toronto, which will be home to our second combination pairing...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
News Preview
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing, $1.2 million in second closing and $2.8 million in t...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion Announces Pricing of Public Offering of Securities
News Preview
SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 11,195,121 shares of its common stock and accompanying warrants to purchase an aggregate of 11,19...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US63909J1088
Nautilus Biotechnology Inc
NAUT
LISTED
NASDAQ
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
News Preview
SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Oct. 7, 2025 /PRNewswire/ -- The law firm ofRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), have until December 2, 2025 to seek appointmen...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
News Preview
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE® (relugolix/estradiol/norethindrone acetate) in Canada....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US75955J4022
Relmada Therapeutics Inc
RLMD
LISTED
NASDAQ
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
News Preview
Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
News Preview
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX® (relugolix) in Canada....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
News Preview
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces $135 Million Private Placement
News Preview
Jade Biosciences Announces $135 Million Private Placement...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
News Preview
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial mar...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US35168W1036
Fractyl Health Inc
GUTS
LISTED
NASDAQ
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
News Preview
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US00973Y1082
Akero Therapeutics Inc
AKRO
LISTED
NASDAQ
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual America...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US67576A1007
Ocular Therapeutix Inc
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
News Preview
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
News Preview
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in pa...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: CA90429T1003
Unbuzzd Wellness Inc.
UNBZ
LISTED
CSE
Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View
News Preview
A New Model for the Modern Issuer BRISTOL, TN / ACCESS Newswire / October 7, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) is quietly redrawing the boundaries of what a biotechnology company can be. The company has evolved beyond traditional R&D into a diversified enterprise-one that integrates clinical innovation, consumer he...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
ISIN: AU0000317281
Percheron Therapeutics Limited
PER
LISTED
ASX
Edison Issues Report on Percheron Therapeutics (PER)
News Preview
London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound's favourable safety an...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: CA90468F1027
Unidoc Health Corp.
UDOC
LISTED
CSE
RETRANSMISSION UniDoc Announces LIFE Offering
News Preview
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, BC / ACCESS Newswire / October 7, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") is pleased to announce a non-brokered private placement LIFE offering (the "Of...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
News Preview
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US52886X1072
Lexeo Therapeutics Inc
LXEO
LISTED
NASDAQ
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
News Preview
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US6551872012
Aclarion, Inc.
ACON
LISTED
NASDAQ
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
News Preview
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies (OTC Pink:MDCE) Outlines Regulatory Roadmap: Dividing AI Health Platform Into Clinical and Consumer Divisions
News Preview
MESA, ARIZONA / ACCESS Newswire / October 7, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in AI-driven preventive healthcare, today announced its strategic plan to separate its artificial intelligence health applications into two distinct divisions - one designed for clinical validation and regulatory approval, and a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US45408X3089
IGC Pharma, Inc
IGC
LISTED
XASE
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
News Preview
IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD, 1734 / ACCESS Newswire / October 7, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company le...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US92829J2033
Virios Therapeutics Inc
DWTX
LISTED
NASDAQ
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
News Preview
ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US83558L2043
Sonoma Pharmaceuticals, Inc.
SNOA
LISTED
NASDAQ
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
News Preview
BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based fa...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
News Preview
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC studyThese data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
News Preview
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease (PD). The data were presented on October 6th at th...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
News Preview
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on ad...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US87975F1049
Telomir Pharmaceuticals, Inc.
TELO
LISTED
NASDAQ
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
News Preview
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models. MIAMI, FLORIDA / ACCESS Newswire / October 7, 2025 / Telomir Pharmaceuticals,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
